Pharmatio GmbH, already established in the monitoring and site liaison of clinical trials, has restructured its services. With Clinical Trial Liaison, the sponsors of clinical trials can ensure the patient recruitment and effectiveness of their clinical trials. The Clinical Trial Task Force masters difficult or unforeseen challenges in clinical trials, and High Quality Monitoring ensures that Pharmatio ensures all-time inspection readiness of clinical trial sites.
Dutch immuno-oncology company Merus has appointed John Crowley its Chief Financial Officer. Former CFO Shelley Margetson has been elevated to Chief Operating Officer.
French cellular immunotherapy company TxCell has hired ex-Novartis Lab Head Li Zhou to lead its CAR-Treg programmes. Zhou was appointed Vice President Cell Engineering in October.
After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest of lung cancer patients.
While DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed at integrating the goals of the European Commissions circular economy and the bioeconomy strategies.
Norwegion immuno-oncology play Targovax has promoted Øystein Soug, previously the companys Chief Financial Officer, to the role of Chief Executive Officer. He succeeds Gunnar Gårdemyr, who has stepped down.
